Tenaya Therapeutics (TNYA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Oct, 2026Executive summary
Special meeting scheduled for Dec. 9, 2026, at 8:00 a.m. Pacific Time; online attendance requires registration. Record date: Oct. 19, 2026.
Voting matters and shareholder proposals
Board recommends FOR authorization of a certificate amendment permitting a reverse stock split; named proxies may vote on other business properly presented at the meeting.
Shareholder rights and capital structure
Proposed split would cover issued and outstanding common shares and treasury shares, at a ratio from 1-for-10 to 1-for-25; the board would select the exact ratio and decide whether to effect it.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Tenaya Therapeutics
- Q3 loss narrowed as TN-201 and TN-401 milestones approach, with cash runway into Q4 2027.TNYA
Q3 2026 - Stockholders face a discretionary reverse split proposal amid Nasdaq bid-price concerns.TNYA
Proxy filing - A discretionary 1-for-10 to 1-for-25 reverse split targets Nasdaq bid-price compliance.TNYA
Proxy filing - Durable clinical improvements and strong market interest drive pivotal planning for gene therapy assets.TNYA
H.C. Wainwright 28th Annual Global Investment Conference - Q4 will bring pivotal regulatory and clinical updates across all major heart disease programs.TNYA
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 net loss rose to $43.4M on impairment; cash runway extends through Q3 2027.TNYA
Q2 2026 - Durable efficacy and safety in gene therapy programs drive pivotal trial plans for 2026.TNYA
Jefferies Global Healthcare Conference 2026 - TN-201 gene therapy produced durable cardiac and symptomatic improvements in MYBPC3-HCM patients.TNYA
Study result - Gene therapy for MYBPC3-HCM shows safety, efficacy, and protocol-related FDA hold; timelines intact.TNYA
Status Update